Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 16/20 | 0.64 |
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 2/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21476146 | 0.89 | FFAR1 (0.52) | FFAR1CYP4F2CYP4A11SYKFFAR4 | |
| SCHEMBL21476702 | 0.87 | FFAR1 (0.66) | FFAR1HTR7FFAR4 | |
| SCHEMBL21475923 | 0.86 | HTR7 (0.57) | FFAR1HTR7CYP4F2CYP4A11SYK | |
| SCHEMBL8903063 | 0.85 | TDP1 (0.56) | FFAR1CYP4F2CYP4A11SYKFFAR4 | |
| SCHEMBL4425984 | 0.85 | CYP4F2 (0.64) | CYP4F2CYP4A11SYK | |
| SCHEMBL30540945 | 0.83 | FFAR1 (0.55) | FFAR1CYP4F2CYP4A11SYK | |
| SCHEMBL9444904 | 0.82 | SYK (0.49) | FFAR1CYP4F2CYP4A11SYK | |
| SCHEMBL21484487 | 0.82 | FFAR1 (0.91) | FFAR1FFAR4 | |
| SCHEMBL12571007 | 0.81 | FFAR1 (0.78) | FFAR1FFAR4 | |
| SCHEMBL1068218 | 0.81 | CYP4F2 (0.55) | CYP4F2CYP4A11SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174228-B2 | Antagonists of human integrin (α4)(β7) | MORPHIC THERAPEUTIC, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20200385352-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2020-12-10 | — | — | US | disclosed |
| WO-2019200202-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174228-B2 | Antagonists of human integrin (α4)(β7) | ITGB7, ITGB4, ITGA4 | FFAR1 2655/4885HTR7 134/4885CYP4F2 3652/4885 |
| US-20200385352-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | ITGB7, ITGB4, ITGA4 | FFAR1 2643/4885HTR7 111/4885CYP4F2 3068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.